Influence of oral moisturizing jelly as a saliva substitute for the relief of xerostomia in elderly patients with hypertension and diabetes mellitus

Supranee Dalodom, MS, DDSa, Aroonwan Lam-ubol, PhD, DDSb, Sutha Jeanmaneechotechai, MS, DDSa, Lalana Takamfoo, DDSc, Watanyoo Intachai, DDSd, Kochaporn Duangchada, DDSd, Buakhao Hongsachum, MS, BSf, Panitnart Kanjanatiwat, MS, BSf,g, Piakamon Vacharotayangul, PhD, DDSb, Dunyaporn Trachootham, PhD, DDS'h,*

aBureau of Dental Health, Department of Health, Ministry of Health, Nonthaburi, Thailand
bFaculty of Dentistry, Srinakharinwirot University, Bangkok, Thailand
cLampang Provincial Public Health Office, Lampang, Thailand
dLampang Hospital, Lampang, Thailand
eJaehom Hospital, Lampang, Thailand
fThe Dental Innovation Foundation under Royal Patronage, His Majesty the King's Dental Service Unit, Bangkok, Thailand
gFood Innovation and Packaging Center, Faculty of Agro-industry, Chiang Mai University, Chiang Mai, Thailand
hInstitute of Nutrition, Mahidol University, Thailand

Abstract

Dry mouth is common in elderly patients. However, the use of saliva substitute has been limited due to its inedibility. This study investigated the efficacy of oral moisturizing jelly (OMJ), a novel edible saliva substitute. A pre-post design was conducted in 118 elderly patients diagnosed with hypertension and/or diabetes mellitus. After using OMJ, signs and symptoms of dry mouth were compared with baseline data. The properties of saliva were compared between the OMJ use and non-use periods. The use of OMJ for 2 weeks significantly reduced symptoms of dry mouth, while the use for 1 month reduced the signs of xerostomia, prevented the decline of salivary pH(s) and improved buffering capacities. OMJ was equally effective in patients taking 1 to 2 and 3 to 7 medications. Furthermore, 65% of patients preferred OMJ over a commercial product. OMJ could be a new edible saliva substitute for elderly patients suffering from dry mouth.

Clinicaltrials.gov ID: NCT02317172.

© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Xerostomia (dry mouth) is a common complaint of almost 50% of elderly population. Although salivation decreases with age, the actual causes of xerostomia in elders are likely drug-induced hyposalivation, head and neck irradiation and systemic conditions, such as Sjögren's syndrome and type 2 diabetes mellitus. Many types of medicine cause dry mouth as a side effect e.g. anti-hypertensive drugs, anti-diabetic drugs, psychotherapeutic drugs and anti-histamines. Owing to the multiple functions of saliva, hyposalivation leads to speech problems, taste disorders, chewing and swallowing difficulties, ill-fitting dentures and consequently poor quality of life. Furthermore, hyposalivation results in decreased oral clearance, declined salivary pH and buffering capacity, and reduced immune defenses. These symptoms may increase risks of developing infectious oral diseases such as cervical caries, periodontitis and oral candidiasis. Current interventions for xerostomia include systemic therapies such as cholinergic agonists; topical interventions such as saliva

0197-4572/© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). http://dx.doi.org/10.1016/j.gerinurse.2015.10.014
stimulants and saliva substitutes, and non-pharmacological interventions such as acupuncture and electrostimulation. Recent evidence-based reviews concluded that systemic salivary stimulants e.g. pilocarpine and cevimeline are recommended only for primary and secondary Sjögren’s syndrome. No topical therapies have strong evidence to support their efficacies. Evidences for acupuncture or electrostimulation devices are insufficient. Thus, the development of novel effective approaches for alleviating xerostomia is essential.

In recent years, saliva substitutes have gained much attention. Saliva substitutes are available in various formulations e.g. lozenges, sprays, mouth rinses, gels, oils, chewing gums or toothpastes. However, no single product could adequately reproduce the properties of the natural saliva. This is likely due to the inedibility of those saliva substitutes. The saliva substitute products usually contain preservatives. Therefore, their uses are limited only to oral cavity and they are not recommended to be swallowed. This constraint has become critical and thus limited the uses of commercially available saliva substitutes. Saliva swallowing is a normal reflex to maintain a proper clearance by eliminating gram-negative bacilli from oropharynx. In fact, oropharyngeal infection and sputum accumulation in patients with xerostomia could increase the risk of aspiration pneumonia. Furthermore, saliva swallowing is critical for food ingestion since the flow of saliva through oropharyngeal isthmus stimulates swallowing process and taste perception in oropharyngeal area. Therefore, the general properties of ideal saliva substitutes should be inexpensive, edible, hydrating, easy-to-swallow but retainable in the mouth.

Recently, oral moisturizing jelly (OMJ) was successfully developed by joint collaborators from various disciplines including dentistry, nursing, medicine and food sciences. OMJ is a ready-to-eat gel with semi-solid appearance but could be melted under oral environment temperature. Upon biting or spooning, the gel will release some water due to syneresis. Since patients with xerostomia often have chewing and swallowing problems, the texture and gel strength of OMJ were designed based on a previous research and development of Nutri-jelly, a nutritious edible gel proven to be effective in improving quality of life in head and neck cancer patients with chewing and swallowing difficulties. Unlike Nutri-jelly, OMJ has no nutrients but contains buffering agents and high water content. In addition, OMJ has neutral pH (6.8–7) and normal buffering capacity, imitating the natural saliva. The most severe xerostomia was found in head and neck cancer patients undergoing radiation therapy. A home-use-test of OMJ was conducted in 36 cancer patients with xerostomia. The patients used the OMJ products for two weeks and recorded their uses and satisfactions in their diaries. The study showed that 82.3% of the cancer patients were satisfied with the texture, flavor and moisture of OMJ. In addition, the satisfaction of OMJ was higher than that of a commercially available saliva gel. After taking one spoon of OMJ, most patients required an additional spoon after 2 h and 45 min, suggesting that OMJ can retain in the mouth for almost 3 h. Although dry mouth is common in elderly population, the intervention studies for treatment of dry mouth in these patients have been limited. Therefore, the aim of this study was to investigate the efficacy of OMJ in elderly patients.

Methods

Intervention

Oral moisturizing jelly (OMJ) products were provided by Dental Innovation Foundation under Royal Patronage, a non-profit organization. The OMJ products passed food safety test (free of pathogenic micro-organisms and hazardous metals), according to the regulation of Thai Food and Drug Administration (FDA). The OMJ products were manufactured in a clean room by hot-filling. The OMJ products have 6-month shelf life at room temperature. Besides, the products are available in two flavors: strawberry and lime mint (Fig. 1a), and their biochemical properties are not different. The products are semi-solid with consistency comparable to National Dysphagic Diet (NDD) level 1, non-nutritive, water-releasing and ready-to-eat by spoon (Fig. 1b).

Participants

Patients were recruited from the out-patient departments of two hospitals located in Lampang province of Thailand. Prior to the recruitment, all patients were screened based on the following inclusion criteria: being diagnosed with hypertension or diabetes mellitus and receiving medical therapies for at least 1 year; having complaint of xerostomia. Exclusion criteria were as follows: having subjective dry mouth score <3 or objective dry mouth score <2; having oral candidiasis; being unable to make reliable decisions or communications. All patients signed their written informed consents prior to data collection. Their identities had been protected, following Good Clinical Practice guidelines of International Conference on Harmonisation (ICH-GCP).

Sample size calculation

Sample size was identified by priori power analysis using G Power 3.1. The effect size was calculated from the pilot data of 10 patients using their mean subjective dry mouth scores and standard deviations at baseline, 2 weeks and 1 month after OMJ use. Based on repeated measure analysis of variance (repeated measure ANOVA), it was necessary to enroll 70 patients to achieve 90% power at 2-sided 1% significance level. To account for an up to 30% drop-out rate, at least 100 patients were required. Initially, 126 patients agreed to be enrolled in the study. Finally, completed data were presented from 118 patients (93.6%).

Study procedures

This study was approved by the institutional ethic committee for research in human of Department of Health, Ministry of Health, Thailand, and performed according to Declaration of Helsinki. To investigate the possible benefits of OMJ, a pre-post design was used. At the beginning, all patients who passed the inclusion criteria signed their written informed consents. Then, all of them received their favorite flavored OMJ products in a volume of 50 ml (10 ml × 5 times) per day. After using the OMJ for 2 weeks and 1 month, their signs and symptoms of xerostomia were measured as objective and subjective dry mouth scores, respectively, and compared with their baseline data (prior to use). Their properties of saliva, including salivary pH(s), buffering capacities and flow rates, were subsequently compared with their baseline data. Since, the patients were also taking other medicines with potential side effects on saliva qualities during the study period, their changes of saliva properties during ‘OMJ use period’ were monitored and compared within the same patients during ‘OMJ non-use’ period. The data for ‘OMJ non-use’ period were collected within the same patients three months later. To ensure that the baseline data of “OMJ use and non-use” periods was comparable, the history of medication uses was rechecked. It was confirmed that all patients received similar medications and doses in both periods.

Measures

The primary outcome measures were satisfaction and subjective dry mouth scores. The secondary outcomes measures were
objective dry mouth scores, salivary pH(s), buffering capacities and flow rates.

**Satisfaction**

At the beginning, all patients had few spoons of OMJ and a commercially available artificial saliva gel, in a random order. Then, they were asked to choose their favorite gel (either OMJ or the commercial one). At the end of the ‘OMJ use’ period, the patients were asked to rate their appreciation for OMJ in a scale of 0–10.

**Subjective dry mouth score**

The patients were interviewed for their symptoms of xerostomia including dry mouth, dry throat, chewing and swallowing difficulties, taste disturbances, speech problems, night-time water intakes and ill-fitting dentures. The patients were advised to give the scores on the severity of symptoms in a scale ranging from 0 (not troublesome) to 10 (most troublesome). The subjective dry mouth scores of each patient were calculated as the mean of all item scores. Patients with a score less than 3 were excluded from data analysis.

**Objective dry mouth score**

The patients were examined for their signs of dry mouth including loss of pooled saliva, mouth mirror stickiness, stringy or foamy appearance, labial dehydration and irresponsiveness to parotid stimulation. Objective dry mouth scores were calculated as the number of observed dry mouth signs (0–5). Patients with a score less than 2 were excluded.

**The properties of saliva**

The various parameters of saliva including salivary pH(s), buffering capacities and flow rates were measured in all patients during OMJ use and non-use periods. As depicted in Fig. 2, the salivary pH(s), buffering capacities and flow rates were measured.
at baseline (prior to OMJ use), and after 2 weeks and 1 month of OMJ use period. Then, all subjects were advised to stop their uses of OMJ for 3 months; thereafter, the measurements were collected as baseline, and after 2 weeks and 1 month of OMJ non-use period. For the measurement of saliva’s properties, whole saliva samples were collected within 10 min after stimulation by paraffin chewing. Stimulated salivary flow rates, pH(s) and buffering capacities were measured by using commercially available GC Saliva Check-Buffer kits (GC Asia, Singapore). This method was feasible in dental offices and was proven to be well-correlated with laboratory titrations. As instructed on the product sheet, salivary flow rates less than 1 ml/min and salivary pH(s) < 6.8 were considered abnormal. Salivary buffering capacities were categorized into very low (score 0–5), low (6–9) and normal (≥10) capacities. The buffering capacities of each patient after using the OMJ for 2 weeks and 1 month were compared with that of his baseline data. Then, they were represented by improved, unchanged or worse buffering capacities. For example, a patient had low buffering capacity at baseline, very low buffering capacity at 2 weeks and low buffering capacity at 1 month. The changes of buffering capacity in this patient would be categorized as worse capacity at 2 weeks and unchanged capacity at 1 month. The percentages of patients in each category (improved, unchanged or worse buffering capacities) were calculated as the number of patients in each category divided by the number of total patients.

Patients with baseline saliva qualities in a normal range i.e. flow rate of > 1 ml/min, pH > 6.8 and buffering capacity score ≥10 were excluded from data analysis.

Statistical analysis

The sample size and power were calculated by G Power 3.1. Data from 118 patients yielded a post-hoc power of 0.95 for repeated measure ANOVA. Graphing and statistical analyses were performed by using Graph Pad Prism 5.0. Descriptive statistics were used to summarize data as follows: mean of subjective and objective dry mouth scores, salivary pH(s) from all patients. The normality of data distributions was verified by the D’Agostino & Pearson omnibus test. Parametric statistical tests were used only when the data passed normality test (p > 0.05). Comparisons of subjective and objective dry mouth scores between 2 weeks, 1 month and baseline measurements were analyzed by using repeated measure ANOVA. The Bonferrini tests identified time points with significance differences from the baseline data. Comparisons of changes in salivary pH(s) between OMJ use and non-use periods were analyzed by using Two-way ANOVA, followed by Tukey’s multiple comparisons. Comparisons of changes in salivary buffering capacities between “OMJ use” and “OMJ non-use” periods or between patients taking 1 to 2 and 3 to 7 medications were analyzed by chi-square tests. Comparisons of subjective and objective dry mouth scores, and salivary pH(s) at different time points between patients taking 1–2 and 3–7 medications were analyzed by Two-way ANOVA. All tests were performed with two-tailed methods (where possible), α = 0.05, p-values < 0.05 were considered statistically significant.
qualities were poor with abnormally low flow rates, acidic pH(s) and low buffering capacities. Consequently, fifty-five percent of them had cavities at the neck of tooth (cervical caries) and forty-seven percent of them had microbial plaque accumulations on their tongues (tongue coating). Due to their dry mouth problems, the patients drank water frequently and their water intakes ranged from 4 to 15 servings/day.

**Satisfaction**

As shown in Fig. 1c, sixty-five percent of the patients selected OMJ as their favorite gels, while 35% preferred the commercial artificial saliva gel. The highest preference of OMJ was correlated with easily swallowing, extra deliciousness and more hydrating. An example of quotes from the patients was, “OMJ is my favorite gel because it can be swallowed similar to natural saliva. Compared to the other brand, OMJ keeps mouth and throat more moisten.” At the end of OMJ use period, the patients provided average appreciation score of 7.98 ± 2.6 (out of 10). Examples of quotes from the patients were: “After using OMJ, I don’t choke while eating”; “OMJ is very helpful. My mouth and throat are no longer dry”; “Previously, frequent water sipping was required when swallowing food. With OMJ, I can freely swallow the food.” Three months later, most patients complained that their dry mouth symptoms returned after stopping OMJ and they had simultaneously requested for OMJ. A great example of quotes from patients was, “Without OMJ, I had dry and sore throat, and excessive coughing with sputum. It was difficult to endure without OMJ and frequent water sipping was required for swallowing of food. I really would like to have OMJ once more.”

**Effect of oral moisturizing jelly on subjective and objective dry mouth scores**

To evaluate the effects of OMJ on symptoms and signs of xerostomia, subjective and objective dry mouth scores after using OMJ were compared with their baseline scores. As shown in Fig. 3a, the average subjective dry mouth scores had 73% and 88% reduction from their baseline data, after using OMJ for 2 weeks and 1 month, respectively ($p < 0.0001$). The results suggested that the repeated uses of OMJ could significantly decrease the symptoms of dry mouth.

![Fig. 3. The effect of OMJ on signs and symptoms of dry mouth and saliva's properties. (a and b) The changes of subjective (a) and objective (b) dry mouth scores during OMJ use period reflected the effect of OMJ on symptoms and signs of dry mouth, respectively. Each bar represented the percentage of the respective scores compared with their baseline scores. Error bars indicated 95% confidence interval. Repeated measured ANOVA tests showed significant changes in subjective ($p < 0.0001$) and objective ($p = 0.0086$) dry mouth scores, compared with baseline data. Bonferrini tests identified time points with significant differences from baseline. (**$p < 0.01$; (***$p < 0.001$). (c) Comparisons of salivary pH(s) between OMJ use and OMJ non-use periods. Each bar represented the mean of salivary pH(s) at various time points; pink — baseline, orange — 2 weeks, green — 1 month. Error bars indicated 95% confidence interval. Two-way ANOVA showed a significant difference between the periods ($p = 0.0015$). Tukey’s tests identified time points with significant differences from baseline. (*) $p < 0.05; (***$ $p < 0.001$. (d) Comparisons of buffering capacities in all patients between OMJ use and OMJ non-use periods. Each stacked bar represented the percentage of patients who had improved (blue), unchanged (orange) and worse (pink) buffering capacities during 1 month of OMJ use or OMJ non-use periods. The chi-square test showed a significant difference between the two periods ($p = 0.035$). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

Fig. 3. The effect of OMJ on signs and symptoms of dry mouth and saliva’s properties. (a and b) The changes of subjective (a) and objective (b) dry mouth scores during OMJ use period reflected the effect of OMJ on symptoms and signs of dry mouth, respectively. Each bar represented the percentage of the respective scores compared with their baseline scores. Error bars indicated 95% confidence interval. Repeated measured ANOVA tests showed significant changes in subjective ($p < 0.0001$) and objective ($p = 0.0086$) dry mouth scores, compared with baseline data. Bonferrini tests identified time points with significant differences from baseline. (**$p < 0.01$; (***$p < 0.001$). (c) Comparisons of salivary pH(s) between OMJ use and OMJ non-use periods. Each bar represented the mean of salivary pH(s) at various time points; pink — baseline, orange — 2 weeks, green — 1 month. Error bars indicated 95% confidence interval. Two-way ANOVA showed a significant difference between the periods ($p = 0.0015$). Tukey’s tests identified time points with significant differences from baseline. (*) $p < 0.05; (***$ $p < 0.001$. (d) Comparisons of buffering capacities in all patients between OMJ use and OMJ non-use periods. Each stacked bar represented the percentage of patients who had improved (blue), unchanged (orange) and worse (pink) buffering capacities during 1 month of OMJ use or OMJ non-use periods. The chi-square test showed a significant difference between the two periods ($p = 0.035$). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Interestingly, as shown in Fig. 3b, there was about 16% reduction of objective dry mouth scores ($p < 0.0086$), after using OMJ for 1 month, while its 2-week use showed a slight (but not significant) decrease of dry mouth signs. These results suggested that the alleviation of dry mouth signs required repeated uses of OMJ for at least 1 month.

**Effect of oral moisturizing jelly on saliva’s properties**

Since all patients were allowed to take their medications for hypertension/diabetes mellitus during OMJ use period, their saliva properties could be fluctuated. To evaluate the actual effect of OMJ on saliva’s properties, their changes in salivary pH(s) and buffering capacities were compared between OMJ use and OMJ non-use periods within the same patients. As shown in Fig. 3c, the mean salivary pH(s) were decreased in a time-dependent manner and become significantly decreased at 1 month during OMJ non-use period. In contrast, the average salivary pH(s) were not decreased during “OMJ use” period. Interestingly, the significant increase in salivary pH(s) toward the normal level was noted after using the OMJ for 2 weeks. Two-way ANOVA analyses showed that salivary pH(s) of OMJ use period were significantly better than that of OMJ non-use period ($p = 0.0015$). Similarly, as shown in Fig. 3d, the number of patients with worse buffering capacities was decreased from thirty two percent in OMJ non-use period, to fifteen percent in OMJ use period. Furthermore, the number of patients with improved buffering capacities was increased from ten percent in OMJ non-use period, to twenty percent in OMJ use period. Statistical analyses showed that salivary buffering capacities of OMJ use period were significantly better than that of OMJ non-use period ($p = 0.035$). Since the patients were a mixed group of very low- (score 0–5) and low- (score 6–9) baseline buffering capacities, separate analyses for each group were performed. As shown in Fig. 4, in the very-low-baseline group salivary buffering capacities after using OMJ for both 2 weeks and 1 month were significantly better than that of OMJ non-use period. In contrast, in the low-baseline group the significance was found only after using OMJ for 1 month. These results suggested that the patients with very-low-baseline buffering capacities were more responsive to OMJ. A slight increase in the salivary flow rates was observed after OMJ use. The average salivary flow rates after 2 week and 1 month OMJ uses were $0.69 \pm 0.53$ ml/min and $0.75 \pm 0.57$ ml/min, respectively, while that of baseline was $0.63 \pm 0.51$ ml/min. However, statistical analyses showed that these differences were not significant ($p = 0.2782$, Krusal–Wallis test).

**Effect of OMJ in the patients based on the number of their medications**

The patients were stratified into two groups based on the number of medications consumed by the patients: (1) taking 3–7 medications ($n = 69$), (2) taking 1–2 medications ($n = 49$). To
investigate whether the number of medications had any effects on the efficacy of OMJ, the changes in subjective and objective dry mouth scores, salivary pH(s) and buffering capacities during ‘OMJ use’ period were compared between the two groups. As shown in Fig. 5, OMJ was very effective in both groups. No significant differences were noted between the two groups after using the OMJ. The buffering capacities were significantly improved in both groups after using OMJ for 2 weeks, as compared to OMJ non-use period (Fig. 6a). In addition, the improved buffering capacities were noted in the 1–2-medication group after using OMJ for 1 month (Fig. 6b right). While in case of the 3–7-medication group, the buffering capacities at 1 month were improved but not significantly, when compared to OMJ non-use period (Fig. 6b left). These results suggested that OMJ might be effective regardless of the number of medications.

**Intervention fidelity**

To ensure treatment fidelity according to NIH Behavioral Change Consortium (BCC), intervention designs for dose, duration and outcome measures were reviewed and agreed by a team of six professional dentists. All patients visited the same hospital for data collections on the same day. On each visit, the data were collected by the same team of researchers to ensure the consistency of the protocol. The assessments of all parameters on each visit were performed by the same researchers in all patients (one researcher for each parameter). The same team of researchers collected data of subjects from the two different hospitals. To enhance the adherence of intervention deliveries, a food sensory testing was performed at the first visit. All patients had few spoons of OMJ (both flavors) and selected their favorite one for further home use.

![Fig. 5. Comparisons of OMJ effects between patients taking 3–7 medications (n = 69) and those taking 1–2 medications (n = 49).](image)
Instructions for using OMJ were carried by a researcher for all patients to ensure consistent deliveries. The treatment receipts (their uses of OMJ) were evaluated by patient diaries (daily records) and patients’ interviews at follow-up visits. The treatment enactment focused on the degree to which the patients continuously received OMJ and returned for dental follow-up visits. Among 126 patients agreed to be enrolled in this study, 118 patients (93.6%) returned for complete follow-up visits and reported continuous daily intake of 50 ml (10 ml/C2 5 times) of OMJ. However, a very small percentage of patients did not adhere to protocols and did not return for follow-up visits.

Discussion

Dry mouth is a critical problem in elderly people with polypharmacy. It could increase the risk of oral diseases, taste dysfunctions, chewing and swallowing difficulties, speech problems and poor qualities of life.25,26 Intra-oral topical agents are among the most commonly recommended treatments for the management of xerostomia.27 Currently, no interventions were proven effective in elderly people diagnosed with systemic diseases.7,8 In general, xerostomia causes dryness in both oral and oropharyngeal mucosa(s), and currently available saliva substitutes are preservative-containing and unsuitable to eat.28 Therefore, they lack bathing effect to oropharynx and their efficacies are limited. Recently, “oral moisturizing jelly (OMJ),” a novel edible gel, was developed to overcome these limitations.13 In this study, a pre-post design was conducted in 118 older people taking medications for hypertension and/or diabetes mellitus. Continuous daily uses of OMJ for 1 month were found to reduce signs and symptoms of dry mouth and improved the saliva’s qualities of elderly patients. Furthermore, OMJ was equally effective in patients taking various medications. This intriguing findings of this investigation demand further randomized control studies.

The efficacy of OMJ more likely resulted from its unique physical and biochemical properties. Unlike other available saliva substitutes, OMJ is edible, easy-to-swallow and hydrating to mouth and throat.13 The design of OMJ’s consistency was based on an insight from research and development of Nutri-jelly, a food gel suitable for cancer patients with chewing and swallowing difficulties.15,16 According to National Dysphagia Diet (NDD) standards for texture modified diets,18 the consistencies of Nutri-jelly and OMJ were likely NDD level 1. Since Nutri-jelly was proved edible by head and neck cancer patients with swallowing difficulties,16 OMJ might also be suitable for individuals with chewing or swallowing difficulties. Since older people often had chewing and swallowing difficulties due to tooth loss and dry mouth,29 future studies should address the effects of OMJ on the improvement of dietary intake in dysphagic older patients.

The moisturizing effect of OMJ more likely resulted from syneresis property; i.e. the release of water from gel upon biting or spooning,14 which rehydrated the dry mouth.13 This was consistent with a previous report showing that the gel formulation appeared to be the most efficient and appreciated by patients among other oral lubricants.30 In addition, the 3-h mouth retention property of OMJ likely allowed continuously hydrating and buffering effects, as shown in other oral care products.31 The use of OMJ for 1 month significantly improved the buffering capacities, when compared to
OMJ non-use period. This finding suggested an efficacy of OMJ. However, it is worth noting that the major proportion of the patients remained unchanged in their buffering capacities after using OMJ (Figs. 3d and 4). This is more likely due to the lack of bicarbonate buffering agents in the OMJ product. Dry mouth problems in the patients of the current study were mainly caused by the side effects of anti-hypertensive/anti-diabetic drugs on autonomic nervous systems. The autonomic nerves stimulate the release of parotid saliva containing bicarbonate buffer. These medications affect the autonomic nervous system and thereby decrease the release of bicarbonate in the saliva. Currently, OMJ contains only phosphate but not bicarbonate buffer systems. Thus, future research to improve the efficacy of OMJ should consider including bicarbonate buffer into this product.

A similar attempt to use a saliva gel in elderly people with abnormal salivary flow rates and buffering capacities had been made. Unfortunately, no significant results were obtained. For example, a prophylactic gel effective in adults with normal salivary function. Gerodontology. 2012;29(2):4972–4980.

Conclusion

Continuous daily uses of OMJ for 1 month reduced the signs and symptoms of xerostomia and improved saliva’s properties of the elderly patients who were taking multiple medications. OMJ is a new edible saliva substitute with potential clinical applications, and thus deserving further exploration in a larger population with a randomized-controlled design.

Acknowledgments

The authors are thankful to all subjects; Ms. Wanna Panyalert, Assoc. Prof. Pattawee Kongkoontian and Mr. Worawut Kulkaew for their research assistances; Dr. S. Dalodom et al. / Geriatric Nursing 37 (2016) 101–109

References